SEC Company Response from IMMUTEP Ltd (IMMP, PRRUF) (CIK 0001506184) (IMMP) — Apr 11, 2012
IMMUTEP Ltd (IMMP, PRRUF) (CIK 0001506184)
Date: April 11, 2012 · CIK: 0001506184 · Accession: 0001193125-12-158924
AI Filing Summary & Sentiment
File numbers found in text: 001-35428
Letter
Acceleration Request
PRIMA BIOMED LTD
Level 7, 151 Maquarie Street
Sydney 2000
New South Wales
Australia
April 10, 2012
VIA EDGAR
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn: Michael Rosenthall
Jeffrey P. Riedler
RE: Prima BioMed Ltd
Registration Statement on Form 20-F (File No. 001-35428)
Ladies and Gentlemen:
The undersigned registrant (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form 20-F to become effective on April 12, 2012, at 4:00 p.m., Eastern Daylight Savings Time, or as soon thereafter as is practicable.
In connection with this request, the Registrant acknowledges that:
•
should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
PRIMA BIOMED LTD
Show Raw Text
CORRESP
1
filename1.htm
Acceleration Request
PRIMA BIOMED LTD
Level 7, 151 Maquarie Street
Sydney 2000
New South Wales
Australia
April 10, 2012
VIA EDGAR
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn:
Michael Rosenthall
Jeffrey P. Riedler
RE:
Prima BioMed Ltd
Registration Statement on Form 20-F (File No. 001-35428)
Ladies and Gentlemen:
The undersigned registrant (the “Registrant”) hereby requests
that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form 20-F to become effective on April 12, 2012, at 4:00 p.m., Eastern Daylight Savings
Time, or as soon thereafter as is practicable.
In connection with this request, the Registrant acknowledges that:
•
should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective,
Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant
from its responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any
person under the federal securities laws of the United States.
Very truly yours,
PRIMA BIOMED LTD
/s/ MARTIN ROGERS
Martin Rogers
Chief Executive Officer